Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).

Autores de I3PT

• 

  Xavier Serra Aracil

  Autor

• Carles Pericay Pijaume

  Autor

• Jesús Badia Closa

  Autor

• Laura Mora López

  Autor

Participantes ajenos a I3PT

• Golda T
• Biondo S
• Hernández P
• Targarona E
• Borda-Arrizabalaga N
• Reina A
• Delgado S
• Vallribera F
• Caro A
• Gallego-Plazas J
• Pascual M
• Álvarez-Laso C
• Guadalajara-Labajo HG

Grupos de Investigación

• Recerca en cirurgia colorrectal

  

  Investigador

  Xavier Serra Aracil

Abstract

The standard treatment of T2-T3ab,N0,M0 rectal cancers is total mesorectal excision (TME) due to the high recurrence rates recorded with local excision. Initial reports of the combination of pre-operative chemoradiotherapy (CRT) and transanal endoscopic microsurgery (TEM) have shown reductions in local recurrence. The TAU-TEM study aims to demonstrate the non-inferiority of local recurrence and the improvement in morbidity achieved with CRT-TEM compared with TME. Here we describe morbidity rates and pathological outcomes.

Keywords

• local excision and rectal cancer, neoadjuvant treatment and rectal cancer, rectal cancer, total mesorectal excision (TME), transanal endoscopic microsurgery (TEM)